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a b s t r a c t 
Co-delivery of anti-cancer drugs is promising to improve the efficacy of cancer treatment. 
This study was aiming to investigate the potential of concurrent delivery of resveratrol (RES) 
and docetaxel (DTX) via polymeric nanocarriers to treat breast cancer. To this end, methoxyl 
poly(ethylene glycol)-poly( d ,l -lactide) copolymer (mPEG-PDLA) was prepared and character- 
ized using FTIR and 1 H NMR, and their molecular weights were determined by GPC. Isobolo- 
gram analysis and combination index calculation were performed to find the optimal ratio 
between RES and DTX to against human breast adenocarcinoma cell line (MCF-7 cells). Sub- 
sequently, RES and DTX were loaded in the mPEG-PDLA micelles simultaneously, and the 
morphology, particle size distribution, in vitro release, pharmacokinetic profiles, as well as 
cytotoxicity to the MCF-7 cells were characterized. IC 50 of RES and DTX in MCF-7 cells were 
determined to be 23.0 μg/ml and 10.4 μg/ml, respectively, while a lower IC 50 of 4.8 μg/ml of 
the combination of RES and DTX was obtained. The combination of RES and DTX at a ratio of 
1:1 (w/w) generated stronger synergistic effect than other ratios in the MCF-7 cells. RES and 
DTX loaded mPEG-PDLA micelles exhibited prolonged release profiles, and enhanced cyto- 
toxicity in vitro against MCF-7 cells. The AUC (0 → t ) of DTX and RES in mPEG-PDLA micelles 
after i.v. administration to rats were 3.0-fold and 1.6-fold higher than that of i.v. injections 
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of the individual drugs. These findings indicated that the co-delivery of RES and DTX using 
mPEG-PDLA micelles could have better treatment of tumors. 
© 2018 Shenyang Pharmaceutical University. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 
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 1. Introduction 
The effect of chemo drug therapy for cancer is confined by
the development of virulent multi drug resistant (MDR) phe-
notypes, which is a major impediment to cancer treatment.
MDR is associated with acquired defense mechanisms, for
instance blocked apoptosis and increased drug efflux [1] .
Combination chemotherapy is one of the strategies used to
overcome the cancer multidrug resistance, which could offer
advantages such as targeting different signal pathways in
cancer cells, and improving the therapeutic index either by
increasing therapeutic efficacy or reducing toxicity [2–5] . 
It has been reported that the co-delivery of combined anti-
cancer drugs to tumor cells using nanocarriers is a hope-
ful strategy for treating MDR [6–7] . Various nanocarriers have
been investigated, including lipid nanoparticles [8] , polymeric
nanoparticles, polymeric micelles [9,10] , liposomes [11] , and
dendrimers [12] , etc. Among them, self-assembly polymeric
micelles are very attractive for co-delivery of multiple anti-
cancer agents. This is because (i) the hydrophobic core could
allow for loading hydrophobic drug compounds such as an-
ticancer drugs; (ii) the outer hydrophilic shell could prolong
circulation time; and (iii) they could provide sustained drug
release profiles. In our previous work, resveratrol (RES) and do-
cetaxel (DTX) have been loaded in mPEG-PDLA micelles sep-
arately [13] . The obtained mPEG-PDLA micelles exhibited pro-
longed release profiles for the two drug compounds. In this
study, we intended to study the potential of co-delivery of RES
and DTX using mPEG-PDLA micelles with respect to the treat-
ment of breast cancer. 
DTX is a widely used antineoplastic agent. However, it of-
ten suffers from drug resistance, resulting in a decrease in the
anti-cancer effect. RES is a sort of phytochemical, which can
be obtained from the roots of white hellebore and different
food sources. It has been reported that RES can down regu-
late the expression of multidrug resistant genes encoded for P-
gp, and inhibit the mammalian target of rapamycin via pyru-
vate kinase isoenzyme type M2, thereby preventing cancer cell
metabolism [14] . It has been observed that RES reinforced cy-
totoxic properties of both anti-cancer drugs through increas-
ing their intracellular level base on P-gp inhibition and down-
regulation of MDR1 [15] . We hypothesized that co-delivery of
RES and DTX could provide synergistic anticancer effect and
generate better treatment effect of cancer than the anti-tumor
with each drug alone. In this study, the synergistic effects of
co-administration of RES and DTX were first investigated. Sub-
sequently, co-delivery of RES and DTX using mPEG-PDLA mi-
celles was evaluated with respect to in vitro release, killing
drug-resistance tumor cells, and pharmacokinetic profiles in
rats. 2. Materials and methods 
2.1. Materials 
d ,l -lactide was purchased from GLACO Ltd. (China). Polyethy-
lene glycol (mPEG2000), stannous octoate (Sn(Oct) 2 ) and 3-[4,
5-dimethyl-2-thiazolyl]-2, 5-diphenyl-2-tetrazolium bromide
(MTT) were purchased from Sigma (USA). Docetaxel was pur-
chased from Shanghai Jinhe Bio-tech Co., Ltd. (China). Resver-
atrol was obtained from Guanyu Bio-tech Co., Ltd. (China).
All other chemicals and solvents were of the highest reagent
grade and used without further purification. 
2.2. Preparation and characterization of mPEG-PDLA 
block copolymer 
mPEG-PDLA block copolymer was prepared by ring-opening
polymerization of appropriate amount of d ,l -lactide
monomer in the presence of polyethylene glycol (mPEG,
Mn = 2000) using stannous octoate as the catalyst in a sealed
tube ( Fig. 1 ). The sealed tube was maintained under 130 °C for
12 h with continuous magnetic stirring. After that, the synthe-
sized polymer was collected by adding some dichloromethane
into the tube and then followed by precipitation in ice-cool
ether for 48 h. The precipitate was filtered, dried at room
temperature under vacuum [16] . 
The molecular structure of the synthesized material was
determined by using FTIR (Bruker, Switzerland), and pro-
ton nuclear magnetic resonance ( 1 H NMR, Bruker ARX-300,
Switzerland). FTIR spectrums were collected using a Bruker
vector 22 analytical FTIR Spectrometer over the region of 400–
4000 cm −1 . The structure, average molecular weight and the
mPEG content of the copolymer were determined by gel per-
meation chromatography (GPC, Waters, USA) and 1 H NMR
in CDCl 3 at 300 Hz. The GPC measurements were conducted
with a Waters 2414 GPC detector instrument equipped with
Styragel® HR THF (7.8 mm ×300 mm) column. THF was used
as eluent at a flow rate of 1.0 ml/min and column thermostat
was set at 35 °C. 
2.3. Screening the ratio of RES to DTX 
The optimal ratio of RES to DTX with respect to antitumor ef-
fect was determined by incubating the two compounds with
MCF-7 cells as reported previously [17] . Briefly, MCF-7 tumor
cells were seeded in a 96-wells plate (6000 cells/well) 12 h prior
to the experiment. Then, the cells were treated with vehicle
Dulbecco’s modified Eagle medium (DMEM) (control group),
DTX (0–50.0 μg/ml, DTX group), RES (0–100.0 μg/ml, RES group),
80 Asian Journal of Pharmaceutical Sciences 14 (2019) 78–85 
Fig. 1 – Synthesis of mPEG-PDLA. 
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ynd combination of DTX and RES (combination group), re- 
pectively. For the combination group, 1.0 ml of DTX and RES 
ith various concentrations were combined in the scheme of 
.5 + 2.5, 5 + 5, 10 + 10, 20 + 20, and 50 + 50 μg/ml and added
nto the wells. Two days after drug stimulation, the optical 
ensity (OD) of each well at 490 nm was measured using a full- 
ave length multi-function microplate reader (Thermo Scien- 
ific Corp., Waltham, USA). Each condition comprised six repli- 
ate wells with at least three independent duplicates. 
.4. Evaluation of synergistic effect of drug combinations 
sing the CI method 
he combination index (CI) was used to evaluate the synergis- 
ic, antagonistic or additive effects of drug combinations [18] ,
hich is calculated by using the following formula: 
I = IC 50ab1 /IC 50a + IC 50ab2 /IC 50b 
here IC 50ab1 , IC 50ab2 are the IC 50 values when the drugs are 
dministered in combination, while IC 50a , IC 50b are the IC 50 
alues when the drugs are administered as single agents.
I > 1 indicates antagonism, CI < 1 indicates synergy and 
I = 1 indicates an additive effect. 
.5. Preparation and characterization of drug-loaded 
PEG-PDLA micelles 
TX and RES loaded mPEG-PDLA micelles were prepared by 
sing the reported solvent casting method [19] . Briefly, DTX,
ES and mPEG-PDLA were dissolved in acetonitrile and then 
dded into a round-bottom flask. A thin and homogenous film 
ontaining the two drugs and polymer was formed after the 
olvent was removed with a rotary evaporator under vacuum 
n a 50 °C water bath. After the film was cooled down to room 
emperature, it was rehydrated in 2.0 ml of deionized water 
ith gentle agitation to form the DTX/RES micelles sponta- 
eously. The resultant micellar colloidal system was filtered 
hrough 0.22 μm filter. 
The particle size and zeta potential of DTX/RES micelles 
ere measured using Malvern Zetasizer Nano-ZS (Malvern 
nstruments Ltd., England). The morphology of DTX/RES mi- 
elles was observed by using a JEM-2100 transmission electron 
icroscopy (TEM, JEOL Ltd., Tokyo, Japan). In sample prepara- 
ion procedure, certain amount of DTX/RES micelles were at- 
ached to copper grids and negatively stained with 2% phos- 
hotungstic acid for 15 s. After the removal of excessive liquid,
he samples were dried in air and subjected to TEM examina- 
ion. .6. In vitro release kinetics of DTX and RES from micelles 
he release profile of DTX and RES from the mPEG-PDLA mi- 
elles was evaluated by using a previously reported method 
ith slight modification [20] . In brief, 1.0 ml of DTX ethanol 
olution (1.0 mg/ml), RES ethanol solution (1.0 mg/ml) and 
TX/RES mPEG-PDLA micelles were placed in dialysis bags 
ith the cutting off M W of 3000 Da. These dialysis bags were 
ncubated in 100 ml of pH 7.4 phosphate buffer containing 
.5% (w/w) Tween 80 to achieve the sink condition and were 
haken in a horizontal shaking water bath (37 ± 0.5 °C) at 
00 rpm for 72 h. At predetermined time intervals, 1.0 ml of 
ample was withdrawn and replaced with an equal volume 
f the fresh released medium. The collected samples were fil- 
ered through 0.22 μm filter and quantified by HPLC. In de- 
ail, the analysis was performed with Hitachi HPLC system 
UV Detector L -2400, Pump L -2130, Hitachi, Tokyo, Japan) and 
 reversed-phase column (Diamonsil, C 18 , 4.6 mm ×250 mm,
 μm). The mobile phase made up of acetonitrile and water 
50:50; v/v) was injected at a flow rate of 1.0 ml/min, and RES
nd DTX was detected at a wavelength of 228 nm. 
.7. Pharmacokinetics studies 
.7.1. Animals 
prague-Dawley rats (male, body weighing about 200 g) ob- 
ained from the Experimental Animal Center at Shenyang 
harmaceutical University (SPU) were employed in pharma- 
okinetic studies. All animal experiments were performed 
trictly in line with guidelines approved by the Life Science Re- 
earch Center at SPU. All efforts were made to limit the num- 
er of animal used and to minimize animal suffering. 
.7.2. Experiment design 
he rats were randomly divided into three groups ( n = 4), i.e.
TX ethanol solution group, RES ethanol solution group and 
TX/RES mPEG-PDLA micelles group. Each sample was in- 
ravenously administered at a dose of 10 mg/kg body weight,
espectively. At given time points (0.083, 0.5, 1, 2, 4, 6, 8,
0, 12 h post injection), 0.5 ml of blood was drawn from the
rbit venous plexus of the rats and placed in heparinized 
ubes. Plasma were immediately separated by centrifugation 
t 5000 rpm for 10 min and stored at −20 °C until further anal-
sis. 
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Table 1 – CI values of different DTX and RES ratios. Data 
represent mean ±SD of three independent experiments 
from five samples for each group. 
DTX:RES (mass ratio) IC 50 (μg/ml) CI value 
DTX RES 
2:1 7.82 ±0.16 3.92 ± 0.12 0.92 
1:1 4.80 ±0.15 4.80 ± 0.17 0.64 
1:2 6.57 ±0.65 13.1 ± 0.24 1.20 
1:0 10.37 ± 0.43 – –
0:1 – 23.03 ± 0.54 –
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2.7.3. Quantitative analysis of DTX and RES in plasma sam-
ples 
For the first step of extraction procedure, 200 μl plasma was
mixed with 20 μl of DTX (10.0 μg/ml) and carbamazepine
(10.0 μg/ml) that was used as the internal standard. DTX and
RES were extracted from plasma with 2.0 ml of methyl tert-
butyl ether by vigorous mixing for 5 min followed by centrifu-
gation at 12,000 rpm for 5 min to separate the organic phase.
The organic phase was collected into a clean tube and evapo-
rated to dryness under nitrogen gas flow at 35 °C. The residue
was dissolved with 100 μl of acetonitrile by vortex-mixing
for 5 min and centrifuged for 5 min at 12,000 rpm. The su-
pernatant was analyzed using the HPLC analysis which was
carried out with Hitachi HPLC system (UV Detector L -2400,
Pump L -2130, Hitachi, Tokyo, Japan). A reversed-phase column
(Diamonsil, C 18 , 4.6 mm ×250 mm, 5 μm) was used. The mo-
bile phase for detecting DTX was made up of acetonitrile and
water (50:50, v/v) eluted at a flow rate of 1.0 ml/min, and for
RES methanol and water (50:50) was used at a flow rate of
1.0 ml/min. The DTX detection was performed at a wavelength
of 228 nm while for RES a wavelength of 306 nm was used. 
2.7.4. PK data analysis 
The pharmacokinetic parameters including maximum con-
centration ( C max ), area under the drug concentration–time
curve (AUC), and total clearance (CL was calculated by using
DAS2.0 software (Mathematical Pharmacology Professional
Committee of China, Shanghai, China). 
2.8. Evaluation of the cytotoxicity of DTX/RES 
mPEG-PDLA micelles 
The cytotoxicity of DTX/RES mPEG-PDLA micelles to MCF-7
cells was evaluated by MTT assay [21] . Free drugs (i.e. DTX and
RES), DTX mPEG-PDLA micelles, and RES mPEG-PDLA micelles
were used as control. The MCF-7 cells were seeded into sterile
96-wells plate (6000 cells/well) and cultured in a cell culture in-
cubator at 37 °C under 5% CO 2 for 16 h. Then the medium was
replaced with 200 μl of fresh culture medium containing the
same amount of free DTX, free RES, DTX mPEG-PDLA micelles,
RES mPEG-PDLA micelles or DTX/RES mPEG-PDLA micelles.
In addition, drug-free mPEG-PDLA micelles was also added as
control. For the group of free DTX and RES, DMSO have to be
used in order to dissolve the drugs, but the final DMSO con-
centration in culture medium was strictly controlled and lim-
ited to 0.02% to minimize its effects on cell viability. After fur-
ther incubation for 48 h, the medium was removed and 100 μl
of MTT solution (0.5 mg/ml) was added into each well. After
4 h, the medium was removed and 100 μl of DMSO was added
to dissolve precipitated formazan crystals and the plate was
shaken for 1 min. The viability of cells was measured with a
microplate reader, and presented as a percentage of the via-
bility ratio. 
2.9. Statistical analysis 
Data were generated in triplicates and expressed as
mean ±S.D. Statistical analysis was performed using Stu-
dent’s t -test with the SPSS 17.0 software. Significance wasdetermined by a P -value of 0.05 (demoted by ∗), P of 0.01
(denoted by ∗∗) and P of 0.001 (denoted by ∗∗∗). 
3. Results and discussion 
The synthesis and characterization of the mPEG-PDLA can be
found in the supplementary material. 
In the following section the co-delivery of RES/DTX loaded
mPEG-PDLA micelles was reported. 
3.1. Evaluation of synergistic effect of DTX and RES 
The potential synergistic effects of DTX and RES were in-
vestigated by measuring IC 50 values of DTX solution, RES
solution, and their combination at different ratio with MTT
assay in MCF-7 cells. The IC 50 of DTX, RES and their combi-
nation at different mass ratio listed in Table 1 suggested that
co-administration of DTX and RES could enhance their cell
proliferation inhibition efficiency. Furthermore, in order to
find the optimal mass ratio between DTX and RES, CI values
of DTX and RES at the ratio of 2:1, 1:1, 1:2 were calculated.
The results showed that CI values varied with the weight
ratio of DTX to RES and the lowest one was obtained at the
ratio of 1:1. It indicated the combination at a mass ratio of 1:1
generated stronger synergistic effect than others. As the mass
ratio increased from 1:1 to 1:2, the synergistic effect flipped
and became an antagonism effect. Therefore, the mass ratio
of 1:1 was chosen as the optimal ratio and was used in the
subsequent preparation of drug-loaded mPEG-PDLA micelles.
In addition, the isobologram analysis was used to evalu-
ate the synergistic effect of the drug compounds ( Fig. 2 ). As a
mathematical approach, isobologram has been used to eval-
uate the drug interactive effects [22] . A particular effect level,
such as 50% of the maximum was selected, and doses of drug
A and B (each drug alone) that gave same effect were plot-
ted. The straight line connecting A and B allows a compari-
son with the actual dose pair that produces this effect level
experimentally. The best combinations can be distinguished.
As shown in Fig. 2 , the points below the straight line sug-
gested that the combination of the two drugs (DTX:RES = 2:1
and 1:1) could generate a synergistic effect in MCF-7 cells. It
was reported that RES could exhibit chemosensitization ef-
fect [23] . RES has been observed to be a chemosensitizer in
docetaxel chemotherapy blocks upregulation and activation
82 Asian Journal of Pharmaceutical Sciences 14 (2019) 78–85 
Fig. 2 – The isobologram of DTX and RES at different ratios. The straight line (additively line) connects the IC 50 values of DTX 
and RES when the drugs were used alone, and the points plotted on the isobolograms were based on the result of Table 1 . 
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sf human epidermal growth factor receptor-2 (HER-2) further- 
ore blocking downstream signaling pathways for instance 
kt [24] . The possible explanation for the synergistic effects 
etween DTX and RES could be that RES down regulated the 
xpression of multidrug resistant gene encoding the mem- 
rane transporter P-gp [25] which inhibits the mammalian 
arget of rapamycin through pyruvate kinase isoenzyme type 
2, thus preventing cancer cell metabolism [26] . The reported 
reatment of combining RES upregulated the pro-apoptotic 
enes (BAX, BID, and BAK), cleaved PARP and down regulated 
he anti-apoptotic genes (MCL-1, BCL-2, BCL-XL) promoting 
poptosis [27] . 
.2. Preparation and characterization of DTX/RES loaded 
PEG-PDLA micelles 
he effect of the process and formulation parameters includ- 
ng the film-forming temperature, the hydration temperature,
nd the drug to polymer ratio on the drug loading/entrapment 
fficiency, size, zeta potential of DTX/RES-loaded mPEG-PDLA 
icelles were investigated and reported in one of our previ- 
us article [28] . In the present study, DTX to RES was fixed at 
:1 and loaded into mPEG-PDLA micelles with the optimized 
rocess and formulation parameters obtained in the previ- 
us article, and the obtained micelles were characterized in 
erms of size, morphology, encapsulation efficiency and drug 
oading efficiency. As shown in Fig. 3 A, DTX/RES-loaded mPEG- 
DLA micelles had a mean particle size of 17.1 ±3.2 nm, and 
DI of 0.27 ± 0.01. The loadings of RES and DTX in the micelles 
re 16.89% and 16.87%, respectively. The TEM images depicted 
n Fig. 3 B revealed that DTX/RES-loaded mPEG-PDLA micelles 
ere spherical and uniform, and the particle size was approxi- 
ately in the range of 20–50 nm, which are slightly larger than he value determined by Marlven Nano ZS Zetasizer Instru- 
ent. 
.3. In vitro drug release of micelles 
he in vitro release results are shown in Fig. 4 . Both RES and
TX exhibited a continuous and fast release in the first 12 h.
fter that, the release rate was slowed down and finally the 
umulative release of both DTX and RES reached nearly 80% 
t 72 h. Furthermore, it was noticed that although the abso- 
ute release percentage of RES was lower than that of DTX,
he release rate of these two drugs was nicely kept to be syn-
hronous, which was very important because it could ensure 
he ratio of DTX to RES (1:1) consistent in tissue to achieve 
he synergistic effect. In contrast to the sustained release pro- 
les of DTX/RES loaded mPEG-PDLA, ca. 80% of DTX and RES 
issolved within 5 h in the release medium. This extended re- 
ease of RES and DTX from the micelles could be attributed 
o the hydrophobic interaction between the drugs and hy- 
rophobic core. The release profiles were fitted with a few 
quations including Higuchi, Peppas and Sahlin model. It was 
ound that the release of RES and DTX from the micelles was 
 combined effect of diffusion and disintegration. It might be 
xplained to the diffusion of the drugs from the core and the 
isintegration of the outer polymeric shell [29] . 
.4. Cytotoxicity of DTX/RES-loaded mPEG-PDLA micelles 
n MCF-7 cells 
he cytotoxicity of DTX/RES loaded mPEG-PDLA against MCF- 
 cells was assessed with MTT study. The results in Fig. 5 ex-
ibited that the blank polymeric micelles did not have any 
ytotoxic effect on the MCF-7 cells, which suggested that the 
ynthesized mPEG-PDLA polymer is safe and biocompatible 
Asian Journal of Pharmaceutical Sciences 14 (2019) 78–85 83 
Fig. 3 – Particle size distribution (A) and TEM image (B) of RES/DTX mPEG-PDLA micelles. 
Fig. 4 – Release profiles of DTX/RES mPEG-PDLA micelles 
( n = 4). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 – Cell viabilities of DTX/RES loaded mPEG-PDLA in 
MCF-7 cells. Significance was determined by P < 0.05 
(demoted by ∗), P < 0.01 (denoted by ∗∗), P < 0.001 (denoted 
by ∗∗∗) as compared to the control group. 
 
 
 with MCF-7 cell line. The DTX/RES loaded mPEG-PDLA showed
the highest cytotoxic activity against MCF-7 cells among the
all treatment groups and led to the death of 70% cells, which
was higher than the effect of micelles containing either the
same concentration of DTX or RES. The increased sensitiv-
ity of DTX/RES loaded mPEG-PDLA micelles in MCF-7 cells
can be attributed to the presence of PEG shell on the surface
which enhanced the uptake mediated through endocytosis.
The copolymer micelles have been demonstrated to be po-
tential nanocarriers for effective intracellular delivery drug to
reverse tumor MDR [30–31] . In addition, co-delivery of the twoTable 2 – Pharmacokinetic parameters of RES solution, DTX solu
injection in rats at a dose of 10 mg/kg ( n = 3). 
PK parameters Formulations 
DTX solution DTX in combination m
t 1/2 (h) 0.66 ± 0.19 2.35 ±0.44 
CL (l/h/kg) 4.30 ± 2.11 1.37 ±0.49 
V (l/kg) 3.79 ± 0.83 4.286 ± 0.82 
AUC (0 −t ) (mg ·h/l) 2.59 ± 1.24 7.91 ±2.78 
AUC (0 −∞ ) (mg ·h/l) 2.64 ± 1.29 8.22 ±3.05 
Note : Data shown as mean ± standard deviation unless otherwise stated. drugs acted on different pathways to evade cell resistance to
DTX [32] . 
3.5. In vivo pharmacokinetic study of DTX/RES-loaded 
mPEG-PDLA micelles 
The PK parameters obtained from the in vivo study ( Table 2 )
showed that mPEG-PDLA micelles largely extended the expos-tion, and RSE/DTX mPEG-PDLA micelles after intravenous 
icelles RES solution RES in combination micelles 
0.34 ±0.13 3.27 ±0.35 
6.34 ±3.54 4.009 ± 2.51 
3.45 ±2.93 18.29 ± 9.82 
1.84 ±1.06 2.93 ±1.79 
1.87 ±1.04 3.10 ±1.94 
84 Asian Journal of Pharmaceutical Sciences 14 (2019) 78–85 
Fig. 6 – Plasma concentration–time curves of RES solution, DTX solution and RSE/DTX mPEG-PDLA micelles after i.v. 
administration to rats ( n = 3). Plasma concentration–time curve of RES (A); Plasma concentration–time curves of DTX (B). The 
inserts are zoom-in of the plasma concentration at first 2 h. 
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 ng time of RES and DTX in the blood circulation ( Fig. 6 ). The
alf-lives of RES and DTX in mPEG-PDLA micelles were about 
 times and 4 times longer than the solutions. In addition, the 
UC (0 → t ) value of RES and DTX when administered as mPEG- 
DLA micelles was about 1.6 times and 3 times higher than 
he solutions. Hydro-PEG could prolong the half-life of drug in 
ats and enhance the targeting and residence time in tumor 
ite [33] . The prolonged blood circulation of the mPEG-PDLA 
icelles can be attributed to its hydrophilic surface composed 
y PEG chain, which endowed the mPEG-PDLA micelles the 
bility of escaping from the reticuloendothelial system, ex- 
ibited a slower clearance. Since tumor tissue possess leaky 
lood vessels and poor lymphatic drainage, micelles may pref- 
rentially accumulate in the solid tumors due to the enhanced 
ermeability and prolonged circulation time [34] and are ex- 
ected to passive targeting to cancer cells to exert the anti- 
ancer effect. 
. Conclusions 
his study demonstrated that the combination of resvera- 
rol and docetaxel could generate synergistic effect against 
CF-7 tumor cells. Co-delivery of resveratrol and docetaxel 
ia methoxyl poly(ethylene glycol)-poly( d ,l -lactide) micelles 
ould not only extend the exposing time of the drug com- 
ounds in blood circulation in rats but also enhanced their 
UC. In addition, the drug combination exhibited improved 
nticancer effect as compared to when each drug compound 
sed alone in vitro . Our findings suggested that the co-delivery 
f resveratrol and docetaxel using methoxyl poly(ethylene 
lycol)-poly( d ,l -lactide) micelles could be promising to treat 
rug-resistant tumors. 
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